Researchers from Cyncado Therapeutics say that TT-4 monotherapy outperforms anti-PD-1 checkpoint inhibitors in treating mesothelioma, and that combining the two improves anti-tumor activity and increased T-cell infiltration even more. The group will be presenting details of its research at the upcoming AACR-NCI-EORTC International Conference to be held in Boston, Massachusetts, this coming weekend. Researchers Focus
The post Preclinical Study Shows Selective A2B Receptor Inhibitor Enhances Mesothelioma Immunotherapy appeared first on Mesothelioma.net.
from Mesothelioma.net https://ift.tt/4xszn38
via IFTTT
Preclinical Study Shows Selective A2B Receptor Inhibitor Enhances Mesothelioma Immunotherapy
![Preclinical Study Shows Selective A2B Receptor Inhibitor Enhances Mesothelioma Immunotherapy]()
Reviewed by Unknown
on
October 23, 2025
Rating:
No comments: